Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05239039 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 39 participants (ACTUAL) |
| Registered Start Date | 2022-03-15 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| The Second Affiliated Hospital Zhejiang University School of Medicine | Hangzhou, China | Open Hospital Dossier -> |
| The First Hospital of China Medical University | Shenyang, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.